Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

The efficacy of a combination of nimotuzumab, a humanized monoclonal antibody to the epidermal growth factor receptor, with chemoradiation in locally advanced head and neck squamous cell carcinoma (HNSCC) was evaluated in a phase II study.

[1]  J. Bourhis,et al.  Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). , 2020, European journal of cancer.

[2]  Kaoru Tanaka,et al.  Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). , 2020 .

[3]  P. Chaturvedi,et al.  A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer , 2019, Cancer.

[4]  A. Argiris,et al.  Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers , 2019, Front. Oncol..

[5]  R. Mesía,et al.  Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma , 2019, Front. Oncol..

[6]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial , 2019, The Lancet.

[7]  C. R. Leemans,et al.  Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial , 2019, The Lancet.

[8]  J. Bourhis,et al.  Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Bourhis,et al.  A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial. , 2018 .

[10]  T. Seiwert,et al.  Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy. , 2018 .

[11]  S. Kannan,et al.  Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Lenz,et al.  Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation , 2017, Cancer treatment reviews.

[13]  R. Orecchia,et al.  Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  R. Ferris,et al.  Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients , 2017, Front. Pharmacol..

[15]  Bingshu E. Chen,et al.  Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial , 2017, JAMA oncology.

[16]  Paolo Bossi,et al.  Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma , 2016, Oncotarget.

[17]  P. Tan,et al.  Interactions between clinical factors, p16, and cyclin‐D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma , 2015, Head & neck.

[18]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[19]  H. Minn,et al.  Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. , 2015, The Lancet. Oncology.

[20]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Shenoy,et al.  Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. , 2014, Oral oncology.

[22]  R. Weber,et al.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Collette,et al.  Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. , 2012, Annals of Oncology.

[24]  Esther Kim,et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[26]  S. Serrano,et al.  Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study , 2010, Clinical Cancer Research.

[27]  M. Frómeta,et al.  Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck , 2010, Cancer biology & therapy.

[28]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[30]  E. Sturgis,et al.  Trends in head and neck cancer incidence in relation to smoking prevalence , 2007, Cancer.

[31]  J. Grandis,et al.  Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[33]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[34]  R. Weber,et al.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.

[35]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[36]  A. Dietz,et al.  Tobacco and alcohol and the risk of head and neck cancer , 1992, The clinical investigator.

[37]  T. Crombet,et al.  Nimotuzumab: beyond the EGFR signaling cascade inhibition. , 2018, Seminars in oncology.

[38]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.